Lincoln Pharmaceuticals Limited LINCOLN NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.lincolnpharma.com

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.

Market & Price

Market Cap

₹1,267.78 Cr

Current Price

₹632.95

High / Low (52W)

₹758.15 / ₹444.20

Beta

0.40

Valuation

Stock P/E

14.43

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹357.45

Price to Book

1.77

P/S

1.94

EV/EBITDA

12.72

Dividend Yield

0.24%

Profitability & Returns

ROCE

15.95%

ROE

ROA

Profit Margin

13.47%

Op Margin

11.95%

EPS (Latest Qtr)

₹14.28

EPS (TTM)

₹43.86

Balance Sheet & Liquidity

Debt/Equity

0.01

Quick Ratio

Current Ratio

Debt

₹6.68 L

Total Assets

₹797.01 Cr

Current Assets

₹499.94 Cr

Working Capital

₹393.72 Cr

Ownership

Promoter Holding

55.10%

Chg in Prom Hold

FII / Inst Holding

1.05%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,286.58 Cr

Total Revenue (TTM)

₹651.94 Cr

EBITDA

₹101.13 Cr

Free Cash Flow

Operating Cash Flow

Shares Outstanding

₹2.00 Cr

Gross Margin

52.76%

Payout Ratio

4.10%

Growth (CAGR)

Revenue 5Y

9.53%

Profit 5Y

5.89%

Revenue (YoY)

13.50%

Earnings (YoY)

37.70%

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LINCOLN Lincoln Pharmaceuticals Limited NSEPHARMA	632.95	14.43	₹1,267.78 Cr	0.24%	15.95%	-	9.53%	5.89%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	-	146.55 Cr	160.20 Cr	154.07 Cr	163.36 Cr	166.32 Cr
Cost of Revenue	-	68.64 Cr	81.47 Cr	69.38 Cr	76.75 Cr	75.96 Cr
Gross Profit	-	77.92 Cr	78.73 Cr	84.68 Cr	86.62 Cr	90.36 Cr
Operating Expenses	-	57.48 Cr	54.62 Cr	64.36 Cr	64.81 Cr	70.49 Cr
Operating Income	-	20.44 Cr	24.10 Cr	20.33 Cr	21.81 Cr	19.88 Cr
EBITDA	-	32.63 Cr	18.95 Cr	39.08 Cr	32.66 Cr	38.74 Cr
Interest Expense	-	72.81 L	-52.03 L	20.98 L	23.07 L	29.81 L
Pretax Income	-	28.68 Cr	16.25 Cr	35.39 Cr	28.81 Cr	34.72 Cr
Tax Provision	-	7.91 Cr	4.67 Cr	7.71 Cr	8.83 Cr	6.12 Cr
Net Income	-	20.77 Cr	11.57 Cr	27.68 Cr	19.98 Cr	28.60 Cr
Diluted EPS	13.15	10.37	-	13.82	9.98	14.28

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	468.20 Cr	504.95 Cr	571.22 Cr	615.25 Cr
Cost of Revenue	219.79 Cr	243.09 Cr	280.02 Cr	292.64 Cr
Gross Profit	248.41 Cr	261.87 Cr	291.20 Cr	322.61 Cr
Operating Expenses	160.01 Cr	181.19 Cr	201.58 Cr	233.40 Cr
Operating Income	88.40 Cr	80.68 Cr	89.62 Cr	89.21 Cr
EBITDA	104.95 Cr	111.28 Cr	133.81 Cr	123.08 Cr
Interest Expense	91.99 L	1.64 Cr	94.63 L	99.57 L
Pretax Income	95.94 Cr	100.48 Cr	122.24 Cr	109.19 Cr
Tax Provision	26.58 Cr	27.58 Cr	28.94 Cr	26.84 Cr
Net Income	69.36 Cr	72.90 Cr	93.30 Cr	82.35 Cr
Diluted EPS	34.63	36.40	46.58	41.11

Compounded Sales Growth

5 Years:	9.53%
1 Year:	13.50%

Compounded Profit Growth

5 Years:	5.89%
1 Year:	37.70%

Stock Price Performance

1 Year:	+17.10%
6 Months:	+19.63%
3 Months:	+2.28%
1 Month:	-5.99%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	534.36 Cr	587.42 Cr	700.29 Cr	797.01 Cr
Current Assets	352.85 Cr	367.21 Cr	437.78 Cr	499.94 Cr
Cash & Equivalents	6.93 Cr	5.05 Cr	5.75 Cr	13.41 Cr
Inventory	72.74 Cr	70.03 Cr	77.17 Cr	78.68 Cr
Receivables	115.94 Cr	136.33 Cr	161.77 Cr	166.40 Cr
Total Liabilities	101.48 Cr	84.95 Cr	107.45 Cr	125.34 Cr
Current Liabilities	90.49 Cr	72.15 Cr	92.28 Cr	106.22 Cr
Long Term Debt	0	-	-	-
Total Debt	2.04 Cr	2.00 Cr	1.07 Cr	-
Total Equity	432.88 Cr	502.47 Cr	592.84 Cr	671.67 Cr
Shares Outstanding	2.00 Cr	2.00 Cr	2.00 Cr	2.00 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	76.13 Cr	39.26 Cr	63.22 Cr	93.02 Cr
Investing Cash Flow	-78.08 Cr	-36.64 Cr	-57.34 Cr	-78.95 Cr
Financing Cash Flow	-2.56 Cr	-4.50 Cr	-5.18 Cr	-6.40 Cr
Capital Expenditure	-45.53 Cr	-14.28 Cr	-39.61 Cr	-19.24 Cr
Free Cash Flow	30.61 Cr	24.98 Cr	23.60 Cr	73.77 Cr
Net Change in Cash	-4.50 Cr	-1.88 Cr	69.52 L	7.67 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	53.1%	51.9%	51.0%	52.4%
Operating Margin %	18.9%	16.0%	15.7%	14.5%
Net Margin %	14.8%	14.4%	16.3%	13.4%
ROE %	16.0%	14.5%	15.7%	12.3%
ROCE %	19.9%	15.7%	14.7%	12.9%

Shareholding Pattern

Insiders

55.10%

Institutions

1.05%

Public Float

2.34%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LINCOLN

No recent headlines available.

LINCOLN · Healthcare